Eli Lilly Cuts Zepbound Weight Loss Drug Prices

Why this matters: The price reduction makes Zepbound more accessible to individuals who may not have insurance coverage or who face high out-of-pocket costs. This increased accessibility could lead to improved health outcomes for those struggling with obesity.

Eli Lilly’s decision to lower the price of Zepbound single-dose vials on its LillyDirect platform marks a significant step in addressing the affordability and accessibility challenges associated with weight loss medications. The price cuts, ranging from $349 to $499 per month to $299 to $449 per month, are designed to provide more options for patients seeking treatment for obesity.

This announcement comes on the heels of agreements between the Trump administration and Eli Lilly and Novo Nordisk to make GLP-1 drugs more affordable and accessible. These agreements aim to lower the prices the government pays for the drugs, introduce Medicare coverage for obesity drugs, and offer discounted medicines through the government’s new direct-to-consumer website, TrumpRx.

Lilly’s move to cut prices on single-dose vials complements its efforts to lower prices on multi-dose pens, pending FDA approval. This dual approach allows more patients to potentially access discounted treatments more quickly.

Novo Nordisk has also responded by lowering the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients. The company has also launched a temporary introductory offer for new patients.

While cutting prices may reduce revenue per medication sold, Eli Lilly’s sales and shares have continued to rise due to the high demand for Zepbound and Mounjaro. The company’s stock has climbed more than 36% this year, reaching a $1 trillion market value.

Zepbound is an injectable prescription medicine that may help adults with obesity or overweight with weight-related medical problems lose excess body weight and keep it off. It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines.

The starting dose of Zepbound single-dose vial (2.5 mg) is available for as low as $299 per month. The 5 mg dose will be available at $399 per month, and all other approved doses are $449 per month for patients in the Zepbound Self Pay Journey Program.

The lower prices are available on LillyDirect, Eli Lilly’s digital healthcare platform (LillyDirect.lilly.com?ref=yanuki.com).

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

Do you think these price cuts will significantly improve access to weight loss treatments? Let us know!

Share this article with others who need to stay ahead of this trend!